Metastatic Castration-Resistant Prostate Cancer: Time for Innovation

References

• Damber JE . Endocrine therapy for prostate cancer. Acta Oncol.44, 605–609 (2005).
   PubMed Web of Science ®Google Scholar
• Scher HI , HalabiS, TannockIet al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol.26, 1148–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Kirby M , HirstC, CrawfordED. Characterising the castration-resistant prostate cancer population: a systematic review. Int. J. Clin. Pract.65(11), 1180–1192 (2011).
   PubMed Web of Science ®Google Scholar
• Saad F , GleasonDM, MurrayRet al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer. Inst.94, 1458–1468 (2002).
   PubMed Web of Science ®Google Scholar
• Tannock IF , de WitR, BerryWRet al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med.351, 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Petrylak DP , TangenCM, HussainMHet al. Docetaxel and estra-mustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med.351, 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Kantoff PW , HiganoCS, ShoreNDet al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363, 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• de Bono JS , OudardS, OzgurogluMet al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet376, 1147–1154 (2010).
   PubMed Web of Science ®Google Scholar
• Fizazi K , CarducciM, SmithMet al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet377(9768), 813–822 (2011).
   PubMed Web of Science ®Google Scholar
• de Bono JS , LogothetisCJ, Molinaet al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med.364, 1995–2005 (2011).
   PubMed Web of Science ®Google Scholar
• Scher HI , FizaziK, SaadFet al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med.367, 1187–1197 (2012).
   PubMed Web of Science ®Google Scholar
• Parker C , NilssonS, HeinrichDet al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med.369(3), 213–223 (2013).
   PubMed Web of Science ®Google Scholar
• Huggins C . Effect of orchiectomy and irradiation on cancer of the prostate. Ann. Surg.115, 1192–1200 (1942).
   PubMedGoogle Scholar
• Mohler Jl . Castration-recurrent prostate cancer is not androgen independent. Adv. Exp. Med. Biol.617, 223–234 (2008).
   PubMed Web of Science ®Google Scholar
• Labrie F , CusanL, GomezJLet al. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J. Steroid Biochem. Mol. Biol.113(1–2), 52–56 (2009).
   PubMed Web of Science ®Google Scholar
• Chen CD , WelsbieDS, TranCet al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med.10(1), 33–39 (2004).
   PubMed Web of Science ®Google Scholar
• Debes JD , TindallDJ. Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med.351(15), 1488–1490 (2004).
   PubMed Web of Science ®Google Scholar
• Hu R , DunnTA, WeiSet al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res.69, 16–22 (2009).
   PubMed Web of Science ®Google Scholar
• Stanbrough M , BubleyGJ, RossKet al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res.66(5), 2815–2825 (2006).
   PubMed Web of Science ®Google Scholar
• Holzbeierlein J , LalP, LaTulippeEet al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol.164(1), 217–227 (2004).
   PubMed Web of Science ®Google Scholar
• Agarwal N , HutsonTE, VogelzangNJet al. Abiraterone acetate: a promising drug for treatment of castration-resistant prostate cancer. Future Oncol.6(5), 665–679 (2010).
   PubMed Web of Science ®Google Scholar
• Sonpavde G , AttardG, BellmuntJet al. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur. Urol.60(2), 270–278 (2011).
   PubMed Web of Science ®Google Scholar
• Attard G , ReidAH, AuchusRJet al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J. Clin. Endocrinol. Metab.97(2), 507–516 (2012).
   PubMed Web of Science ®Google Scholar
• Pia A , VignaniF, AttardGet al. Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. Cancer Treat. Rev.39(8), 966–973 (2013).
   PubMed Web of Science ®Google Scholar
• Attard G , ReidAH, A’hernRet al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol.27, 3742–3748 (2009).
   PubMed Web of Science ®Google Scholar
• Reid AH , AttardG, DanilaDCet al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol.28(9), 1489–1495 (2010).
   PubMed Web of Science ®Google Scholar
• Danila DC , MorrisMJ, de BonoJSet al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol.28(9), 1496–1501 (2010).
   PubMed Web of Science ®Google Scholar
• Fizazi K , ScherHI, MolinaAet al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled Phase 3 study. Lancet Oncol.13, 983–992 (2012).
   PubMed Web of Science ®Google Scholar
• Ryan CJ , SmithMR, de BonoJSet al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med.368, 138–148 (2013).
   PubMed Web of Science ®Google Scholar
• Rathkopf DE , SmithRE, de BonoJSet al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur. Urol. doi: 10.1016/j.eururo.2014.02.056 (2014) ( Epub ahead of print).
   Google Scholar
• Matsunaga N , KakuT, OjidaAet al. C(17,20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17–20)-lyase inhibitors. Bioorg. Med. Chem.12, 4313–4336 (2004).
   PubMed Web of Science ®Google Scholar
• Niraula S , ChiK, JoshuaAM. Beyond castration-defining future directions in the hormonal treatment of prostate cancer. Horm. Cancer.3, 3–13 (2012).
   PubMed Web of Science ®Google Scholar
• Dreicer R , MacleanD, SuriAet al. Phase 1/2 trial of orteronel (TAK-700) – an investigational 17,20-lyase inhibitor – in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res.20, 1335–1344 (2014).
   PubMed Web of Science ®Google Scholar
• Dreicer R , JonesR, OudardSet al. Results from a Phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial). Presented at: 2014 Genitourinary Cancer Symposium.San Francisco, CA, USA, 29 January–2 February 2014.
   Google Scholar
• Taplin ME , MontgomeryRB; ARMOR2 Group. ARMOR2: galeterone in progressive CRPC patients who have failed oral therapy. Presented at: 2014 Genitourinary Cancers Symposium.San Francisco, CA, USA, 29 January–2 February 2014.
   Google Scholar
• Tran C , OukS, CleggNJet al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science324, 787–790 (2009).
   PubMed Web of Science ®Google Scholar
• Scher HI , BeerTM, HiganoCSet al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase 1–2 study. Lancet375, 1437–1446 (2010).
   PubMed Web of Science ®Google Scholar
• Beer TM , ArmstrongAJ, SternbergCNet al. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of Phase III PREVAIL study. Presented at: 2014 Genitourinary Cancer Symposium.San Francisco, CA, USA, 29 January–2 February 2014.
   Google Scholar
• Antonarakis ES , LuC, WangHet al. Androgen receptor splice variant-7 predicts resistance to enzalutamide in patients with castration-resistant prostate cancer. Presented at: American Association for Cancer Research Annual Meeting 2014.San Diego, CA, USA, 5–9 April 2014.
   Google Scholar
• Clegg NJ , WongvipatJ, JosephJDet al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res.72, 1494–1503 (2012).
   PubMed Web of Science ®Google Scholar
• Rathkopf DE , MorrisMJ, FoxJJet al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J. Clin. Oncol.31, 3525–3530 (2013).
   PubMed Web of Science ®Google Scholar
• Smith MR , AntonarakisES, RyanCJet al. ARN-509 in men with high risk non metastatic castration-resistant prostate cancer. Presented at: European Cancer Congress 2013 (ECCO–ESMO–ESTRO).Amsterdam, The Netherlands, 28 September–1 October 2013.
   Google Scholar
• Leibowitz-Amit R , JoshuaAM. Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr. Oncol.19(Suppl. 3), 22–31 (2012).
   PubMed Web of Science ®Google Scholar
• Garcia JA , KatajaVV, JamesNDet al. Bone and soft tissue response from a Phase I/II study with ODM-201 in metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2014 Genitourinary Cancer Symposium.San Francisco, CA, USA, 29 January–2 February 2014.
   Google Scholar
• Giannakakou P , NakanoM, NicolaouKCet al. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc. Natl Acad. Sci. USA99, 10855–10860 (2002).
   PubMed Web of Science ®Google Scholar
• Thadani-Mulero M , NanusDM, GiannakakouP. Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res.72, 4611–4615 (2012).
   PubMed Web of Science ®Google Scholar
• Berthold DR , PondGR, SobanF, de WitR, EisenbergerM, TannockIF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol.26, 242–245 (2008).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G , BuonerbaC, FaiellaAet al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int.107, 234–239 (2011).
   PubMed Web of Science ®Google Scholar
• Caffo O , PappagalloG, BrugnaraSet al. Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. Urology79(3), 644–649 (2012).
   PubMed Web of Science ®Google Scholar
• Bouchet BP , GalmariniCM. Cabazitaxel. A new taxane with favorable properties. Drugs Today (Barc.)46, 735–742 (2010).
   PubMed Web of Science ®Google Scholar
• Mita AC , DenisLJ, RowinskyEKet al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res.15, 723–730 (2009).
   PubMed Web of Science ®Google Scholar
• Guise T . Examining the metastatic niche: targeting the microenvironment. Semin. Oncol.37(2s), S2–S14 (2010).
   PubMedGoogle Scholar
• Tucci M , MoscaA, LamannaGet al. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer Prostatic Dis.12, 94–99 (2009).
   PubMed Web of Science ®Google Scholar
• Baron R , FerrariS, RussellRGG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone48, 677–692 (2011).
   PubMed Web of Science ®Google Scholar
• Saad F , GleasonDM, MurrayRet al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst.96, 879–882 (2004).
   PubMed Web of Science ®Google Scholar
• Pinto A , CruzP. Radium-223 chloride. A new treatment option for metastatic castration-resistant prostate carcinoma. Drugs RD12(4), 227–233 (2012).
   PubMedGoogle Scholar
• Humphrey PA , ZhuX, ZarnegarRet al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol.147(2), 386–396 (1995).
   PubMed Web of Science ®Google Scholar
• Zhang S , ZhauHE, OsunkoyaAOet al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol. Cancer9, 1–13 (2010).
   PubMed Web of Science ®Google Scholar
• Humphrey PA , HalabiS, PicusJet al. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: results from Cancer and Leukemia Group B 150005/9480. Clin. Genitourin. Cancer4(4), 269–274 (2006).
   PubMed Web of Science ®Google Scholar
• Timar J , DomeB. Antiangiogenic drugs and tyrosine kinases. Anticancer Agents Med. Chem.8, 462–469 (2008).
   PubMed Web of Science ®Google Scholar
• Smith DC , SmithMR, SweeneyCet al. Cabozantinib in patients with advanced prostate cancer: results of a Phase II randomized discontinuation trial. J. Clin. Oncol.31, 412–419 (2012).
   PubMedGoogle Scholar
• Saad F , LiptonA. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat. Rev.36(2), 177–184 (2010).
   PubMed Web of Science ®Google Scholar
• Araujo JC , MathewP, ArmstrongAJet al. Dasatinib combined with docetaxel for castration resistant prostate cancer: results from a Phase 1–2 study. Cancer118, 63–71 (2012).
   PubMed Web of Science ®Google Scholar
• Araujo JC , TrudelGC, SaadFet al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind Phase 3 trial. Lancet Oncol.14(13), 1307–1316 (2013).
   PubMed Web of Science ®Google Scholar
• Taylor BS , VaramballyS, ChinnaiyanAM. Differential proteomic alterations between localised and metastatic prostate cancer. Br. J. Cancer95, 425–430 (2006).
   PubMed Web of Science ®Google Scholar
• Joniau S , AbrahamssonPA, BellmuntJet al. Current vaccination strategies for prostate cancer. Eur. Urol.61, 290–306 (2012).
   PubMed Web of Science ®Google Scholar
• Small E , SchellhammerP, HiganoCet al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol.24, 3089–3094 (2006).
   PubMed Web of Science ®Google Scholar
• Higano CS , SchellhammerPF, SmallEJet al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer115, 3670–3679 (2009).
   PubMed Web of Science ®Google Scholar
• Kantoff PW , SchuetzTJ, BlumensteinBAet al. Overall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration resistant prostate cancer. J. Clin. Oncol.28, 1099–1105 (2010).
   PubMed Web of Science ®Google Scholar
• Tollefson MK , KarnesRJ, ThompsonRHet al. A randomized Phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer. Presented at: 2010 Genitourinary Cancers Symposium.San Francisco, CA, USA, 5–7 March 2010.
   Google Scholar
• Slovin SF , HiganoCS, HamidOet al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter Phase I/II study. Ann. Oncol.24, 1813–1821 (2013).
   PubMed Web of Science ®Google Scholar
• Kwon ED , DrakeCG, ScherHIet al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicenter, randomized, double blind, Phase 3 trial. Lancet Oncol.15, 700–712 (2014).
   PubMed Web of Science ®Google Scholar
• Drake CG , AntonarakisES. Update: immunological strategies for prostate cancer. Curr. Urol. Rep.11, 202–207 (2010).
   PubMedGoogle Scholar
• Raymond E , DalgleishA, DamberJEet al. Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother. Pharmacol.73, 1–8 (2014)
   PubMed Web of Science ®Google Scholar
• Pili R , HaggmanM, StadlerWMet al. Phase II randomized, double-blind, placebo controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J. Clin. Oncol.29(30), 4022–4028 (2011).
   PubMed Web of Science ®Google Scholar
• Higano CS . Potential use of custirsen to treat prostate cancer. Oncotargets Ther.6, 785–797 (2013).
   PubMed Web of Science ®Google Scholar
• Chi KN , HotteSJ, YuEYet al. Randomized Phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol.28, 4247–4254 (2010).
   PubMed Web of Science ®Google Scholar
• Saad F , HotteS, NorthSet al. Randomized Phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06. Clin. Cancer Res.17, 5765–5773 (2011).
   PubMed Web of Science ®Google Scholar
• van Soest RJ , van RoyenME, de MorreeESet al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur. J. Cancer49, 3821–3830 (2013).
   PubMed Web of Science ®Google Scholar
• Mezynski J , PezaroC, BianchiniDet al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann. Oncol. 23, 2943–2947 (2012).
   PubMed Web of Science ®Google Scholar
• Schweizer MT , ZhouXC, WangHet al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur. Urol.66(4), 646–652 (2014).
   PubMed Web of Science ®Google Scholar
• Armstrong A , Garrett-MayerE, YangYet al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin. Cancer Res.13, 6396–6403 (2007).
   PubMed Web of Science ®Google Scholar
• Armstrong A , GeorgeD. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis.13, 108–116 (2010).
   PubMed Web of Science ®Google Scholar
• Loriot Y , MassardC, AlbigesLet al. Personalizing treatment in patients with castrate-resistant prostate cancer: a study of predictive factors for secondary endocrine therapies activity. Presented at: 2012 ASCO Annual Meeting.Chicago, IL, USA, 1–5 June 2012.
   Google Scholar
• Azria D , MassardC, TosiDet al. An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): predictive parameters of response. Presented at: 2012 ASCO Annual Meeting.Chicago, IL, USA, 1–5 June 2012.
   Google Scholar
• Efstathiou E , TitusM, WenASet al. The effects of enzalutamide in combination with abiraterone acetate in patients with bone metastatic castration resistant prostate cancer. Presented at: European Cancer Congress 2013 (ECCO–ESMO–ESTRO).Amsterdam, The Netherlands, 28 September–1 October 2013.
   Google Scholar
• Antonarakis ES , EisenbergerMA. Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J. Clin. Oncol.31(14), 1709–1712 (2012).
   Web of Science ®Google Scholar